REGENXBIO Inc - RGNX Enterprise Value to EBITDA Ratio
The EV/EBITDA market trend for REGENXBIO Inc. (RGNX) is 0.00. REGENXBIO Inc. (RGNX) has built a biotech ecosystem around the NAV system, where patent restrictions on the use of AAV vectors create a high level of dependency for external partners. This architecture serves as the foundation for treating severe pathologies. High trial costs and FDA regulations form a powerful defensive barrier, protecting the developer's intellectual capital.
RGNX (regenxbio.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- issuer market value details:
- business book valuation details:
- company total debt and liquidity indicators:
- financial results and valuation multiples details:
RGNX - Net Income|Future Profit REGENXBIO Inc.|RGNX - Business Payback Period|Future Price to Earnings REGENXBIO Inc.|RGNX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple REGENXBIO Corp|RGNX - Operating profit before depreciation charges|Earnings per share for the last twelve months REGENXBIO|RGNX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months regenxbio.com|RGNX - Earnings per share growth this year|Earnings growth forecast for next year REGENXBIO Inc.
- sales revenue and business income indicators:
Summary company analysis:Regenxbio RGNX
REGENXBIO Inc. is developing a diversified gene therapy portfolio, mitigating risks through the licensing of its NAV platform. The EV/EBITDA ratio relates the total enterprise value, net of cash, to its operating profitability before taxes and amortization. Investors utilize this tool to determine if an asset is overbought relative to its generated cash flow. By analyzing the historical EV/EBITDA trend of REGENXBIO Inc., one can identify phases of undervaluation prior to potential price growth.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|QGEN: Enterprise Value to Operating Income Before Depreciation|IONS: Enterprise Value to EBITDA Ratio|RGEN (repligen.com) - Enterprise Value to Operating Income Before Depreciation|RNA: EV/EBITDA Multiple|CRSP (CRISPR Therapeutics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|SRPT - Company Value to EBITDA|Twist Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TXG|Intellia - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Stoke Corp STOK|BioLife Solutions, Inc. (BLFS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation WVE|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|Enterprise Value to EBITDA Ratio PRME (Prime Medicine Corp)|Total Company Value to Operating Income Before Depreciation Ratio Taysha Corp|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure N.V. QURE|Business Value to Operating Income Before Depreciation MGTX|Solid Biosciences - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Ocugen Inc (OCGN)|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation BNTC|Enterprise Value to EBITDA Ratio DSGN|Enterprise Value to Operating Income Before Depreciation RCKT (rocketpharma.com)|EV/EBITDA Multiple FDMT|lexeotx.com - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|PRQR - EV/EBITDA Multiple|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Sangamo Therapeutics Inc. - Business Value to Operating Income Before Depreciation|NAUT (Nautilus Biotechnology, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA Metagenomi Therapeutics MGX|EV/EBITDA Multiple DTIL|generationbio.com (GBIO) - Enterprise Value to EBITDA Multiple|EV/EBITDA Multiple BOLD (Boundless Bio)|Exicure Inc. (XCUR) - Company Value to EBITDA|IMNN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PHIO (Phio Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APDN|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|singulargenomics.com (OMIC) - Company Value to EBITDA|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals Inc.)|TBIO: EV/EBITDA Multiple|TCON - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
